Peptide YY research: molecular processing and Y-receptor assay design

1) Treat PYY(1–36) and PYY(3–36) as different reagents

Peptide YY is a 36-residue, C-terminally amidated member of the pancreatic-polypeptide-fold family. The two-residue difference between PYY(1–36) and PYY(3–36) is small in mass but large in pharmacological meaning. Full-length PYY can activate more than one Y-receptor subtype, whereas removal of the N-terminal Tyr-Pro sequence strongly favors Y2-receptor recognition. A vial labeled only “PYY” therefore leaves the critical experimental variable undefined.

For every lot, record the complete sequence, residue numbering, C-terminal amidation, counterion, peptide content, purity method, supplier, and storage history. Confirm intact mass by LC-MS. Chromatography should distinguish the full-length peptide from the two-residue-truncated product and from later degradation fragments. Because a high percentage purity does not establish correct molecular identity or absolute peptide content, concentration calculations should use the supplier’s peptide-content value when available and should be checked by an independent quantitative method for high-stakes comparisons.

The PP-fold is also sensitive to experimental modification. Fluorescent tags, linkers, biotin, terminal substitutions, or oxidation can change affinity, adsorption, and proteolysis. Compare every labeled or modified ligand with the unmodified parent in the same receptor and signaling assays. Include a vehicle-matched control for carriers or solubilizing additives, and qualify low-binding plasticware if nominal concentrations approach the lower end of the assay window.

2) Make peptidase activity an experimental variable

Grandt and colleagues showed that dipeptidyl peptidase IV—now commonly termed DPP4 or CD26—efficiently removed Tyr-Pro from PYY(1–36), generating the Y2-selective PYY(3–36) form.^[1] This conversion means that a nominal full-length exposure can become a mixed-ligand experiment during incubation. Serum, tissue preparations, primary cells, and some engineered cell lines may contribute different amounts of extracellular peptidase activity.

Medeiros and Turner resolved a broader processing network with purified peptidases and human kidney and jejunal brush-border preparations. DPP4 generated PYY(3–36), aminopeptidase P removed the N-terminal tyrosine, and endopeptidase 24.11—now called neprilysin—cleaved PYY efficiently at an internal site associated with inactivation.^[2] The important laboratory lesson is that disappearance of PYY(1–36) does not imply quantitative appearance of active PYY(3–36). Product identity must be measured.

Run a matrix-stability experiment before the functional plate. Incubate the exact peptide lot in the final medium, with and without cells, and sample at zero, intermediate, and terminal times. Use a validated LC-MS method capable of resolving PYY(1–36), PYY(3–36), and the most plausible fragments. Heat-inactivated serum, peptidase-free buffer, or inhibitors can help assign the mechanism, but inhibitors require their own controls because they may change cell signaling or transport independently.

3) Resolve Y1, Y2, Y4, and Y5 instead of assuming Y2

The human Y-receptor system includes Y1, Y2, Y4, and Y5, all class A GPCRs. PYY shares this receptor family with neuropeptide Y and pancreatic polypeptide. PYY(3–36) is useful as a Y2-preferring probe, but “preferring” is not the same as absolutely selective in every species, construct, expression level, or endpoint. Full-length PYY is less subtype-restricted and should be evaluated across the receptor panel.

Create matched single-receptor cell lines and retain a parental line. Record the receptor species, accession, complete construct sequence, tag position, host background, selection method, and passage range. Quantify receptor at the plasma membrane rather than assuming that equal DNA or total fluorescence produces equal functional expression. Receptor reserve can compress potency differences and make a weak off-target interaction appear robust in an amplified assay.

Dumont and colleagues tested fluorescent PP-fold ligands in rat Y1, Y2, Y4, and Y5 systems. Their BODIPY-FL–PYY(3–36) probe competed at Y2 and Y5 sites but showed little affinity in Y1 and Y4 assays; the labeled ligands also inhibited forskolin-stimulated cAMP, demonstrating retained agonism under their conditions.^[3] This result is a useful warning: even a commonly used Y2 probe requires a subtype panel, and a fluorescent conjugate needs pharmacological requalification.

For causal assignment, require loss of signal in parental or receptor-knockout cells and restoration with a sequence-verified rescue. Antagonists can strengthen the conclusion, but a single antagonist is not definitive when equilibrium, species selectivity, probe dependence, or partial agonism is uncertain. A same-day ligand matrix containing PYY(1–36), PYY(3–36), NPY, and pancreatic polypeptide provides a practical family-level selectivity check.

4) Pair an amplified cAMP assay with proximal Gi/o measurement

Y receptors commonly couple to inhibitory G proteins, making inhibition of forskolin-stimulated cAMP a convenient readout. That assay is highly sensitive but depends on forskolin concentration, receptor abundance, phosphodiesterase activity, incubation time, sensor range, and basal cAMP. Establish a forskolin concentration that provides a stable dynamic window without saturating the detector. Report full concentration–response curves, maximal effect, potency with confidence intervals, and the hierarchy of technical and biological replicates.

Pair cAMP with a proximal measure such as mini-Gi recruitment, heterotrimer dissociation, nucleotide exchange, or GTPγS binding. The proximal assay tests receptor–G-protein engagement with less pathway amplification. Agreement across binding, proximal coupling, and cAMP supports a coherent mechanism; disagreement can reveal receptor reserve, biased signaling, poor ligand recovery, or a sensor artifact.

Include a receptor-independent control that drives or suppresses cAMP downstream of the receptor. This confirms that a knockout, inhibitor, transfection condition, or peptide vehicle has not broadly damaged the signaling machinery. Time courses are essential when ligand processing and receptor desensitization occur on similar timescales. A single late endpoint can merge initial receptor activation, conversion from PYY(1–36) to PYY(3–36), and subsequent adaptation into one uninterpretable value.

5) Separate affinity, efficacy, and ligand trafficking

A functional EC50 is not a binding affinity. Establish recognition with saturation or competition binding, explicitly defining temperature, membrane or whole-cell format, incubation time, nonspecific binding, tracer concentration, receptor density, and equilibrium evidence. Convert IC50 to Ki only when the probe affinity and competition assumptions are justified. Measure maximal signaling separately because two ligands can have similar affinity but different efficacy.

Fluorescent PYY probes can reveal surface binding and ligand uptake, but fluorescence inside a cell does not by itself demonstrate receptor internalization. Prove receptor dependence with parental cells and displacement by excess unlabeled ligand. Distinguish surface from internal signal using an extracellular quencher, acid wash, or validated image segmentation. Include a fluorescent free-dye or matched linker control to identify membrane partitioning and endosomal accumulation unrelated to the receptor.

Dumont and colleagues observed subtype-dependent binding characteristics and time-dependent internalization for some labeled Y-receptor ligands.^[3] Their work supports fluorescent probes as useful tools while also showing why each conjugate must be tested for affinity, selectivity, and agonism. If receptor trafficking is the primary question, label the receptor independently and quantify ligand–receptor colocalization over time rather than treating ligand fluorescence as a receptor surrogate.

6) Validate recombinant findings in native preparations carefully

Native tissue preserves endogenous receptor abundance, peptidases, neural inputs, and epithelial organization, but it complicates attribution. Cox and Tough compared Y-receptor agonists and antagonists in isolated human colonic mucosa. They found evidence for Y1- and Y2-mediated inhibitory tone, with PYY and NPY responses involving both receptor types; pharmacological and tetrodotoxin sensitivity also indicated distinct neural and epithelial components.^[4] A tissue response therefore cannot be assigned to one receptor from ligand name alone.

For native-cell or tissue studies, measure PYY molecular forms in the bathing medium, document anatomical source and preparation interval, and record donor or animal variables permitted by the protocol. Combine transcript measurements with a validated protein, binding, or functional method. GPCR antibody staining without genetic validation is insufficient for low-abundance receptor assignment.

Use receptor-selective perturbations in combinations, verify antagonist activity in matched recombinant controls, and include tetrodotoxin only when distinguishing neural from non-neural contributions is relevant. Monitor tissue viability with a receptor-independent stimulus before and after the PYY experiment. Conclusions should remain at the scale of the preparation: a receptor-dependent change in cAMP, ion transport, electrophysiology, or trafficking establishes a laboratory mechanism under the tested conditions, not a clinical outcome.

7) A reproducible PYY assay workflow

1. Lock chemical identity. Record sequence, residue range, amidation, counterion, peptide content, purity, lot, and intact mass.
2. Measure conversion. Resolve PYY(1–36), PYY(3–36), and inactivating fragments across the actual exposure window.
3. Define the receptor panel. Verify constructs and quantify surface Y1, Y2, Y4, and Y5 where relevant.
4. Prove receptor causality. Use parental, knockout, rescue, and receptor-competence controls.
5. Triangulate pharmacology. Combine binding, proximal Gi/o engagement, and cAMP rather than relying on one endpoint.
6. Qualify modified probes. Re-establish affinity, efficacy, subtype selectivity, and nonspecific uptake after labeling.
7. Predefine analysis. State curve models, replicate hierarchy, exclusion rules, randomization, and uncertainty reporting.

A rigorous PYY experiment follows the molecule as well as the signal. It distinguishes PYY(1–36) from PYY(3–36), measures processing in the assay matrix, resolves the complete receptor context, and links receptor binding to proximal Gi/o activation before interpreting amplified or tissue-level outputs.